Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIGMS Study

• Tanuja Chitnis,
• Angelo Ghezzi,
• Kumaran Deiva,
• Peter Huppke,
• Brenda Banwell,
• Lauren Krupp,
• Emmanuelle Waubant,
• Jutta Gaertner,
• Virginia DeLasHeras,
• Amin Azmon,
• Rajesh Karan

Affiliations

Tanuja Chitnis

5 Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, Boston, Massachusetts, USA

Angelo Ghezzi

2Hospital of Gallarate, Gallarate (VA), Italy

Kumaran Deiva

1 Department of Pediatric Neurology, National Referral Center for Rare Inflammatory Brain and Spinal Diseases, Hopitaux Universitaires Paris-Sud, Le Kremlin-Bicetre, France

Peter Huppke

3 Department of Pediatrics and Adolescent Medicine, German Center for Multiple Sclerosis in Childhood and Adolescence, University Medical Center Göttingen, Gottingen, Germany

Brenda Banwell

4 Perelman School of Medicine, University of Pennsylvania, Children`s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA

Lauren Krupp

6 Pediatric MS Center, NYU Langone Health, New York City, New York, USA

Emmanuelle Waubant

7 Department of Neurology, University of California San Francisco, San Francisco, California, USA

Jutta Gaertner

5 Department of Pediatrics and Adolescent Medicine, German Centre for Multiple Sclerosis in Childhood and Adolescence University Medical Centre, Göttingen, Germany

Virginia DeLasHeras

9 Global Medical Affairs, Novartis Pharma AG, Basel, Switzerland

Amin Azmon

10 Biostatistics, Novartis Pharma AG, Basel, Switzerland

Rajesh Karan

11 Global Drug Delivery, Novartis Pharma AG, Basel, Switzerland